These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 3161209)

  • 1. The plasma inhibitors of plasminogen activator, studied by a zymographic technique.
    Booth NA; Anderson JA; Bennett B
    Thromb Res; 1985 May; 38(3):261-7. PubMed ID: 3161209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet release protein which inhibits plasminogen activators.
    Booth NA; Anderson JA; Bennett B
    J Clin Pathol; 1985 Jul; 38(7):825-30. PubMed ID: 3926830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The irreversible inhibition of urokinase, kidney-cell plasminogen activator, plasmin and beta-trypsin by 1-(N-6-amino-n-hexyl)carbamoylimidazole.
    Walker B; Elmore DT
    Biochem J; 1984 Jul; 221(1):277-80. PubMed ID: 6235806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Detection and partial characterization of a specific plasminogen activator inhibitor in human chondrocyte cultures.
    Yamada H; Stephens RW; Nakagawa T; McNicol D
    J Biochem; 1988 Dec; 104(6):960-7. PubMed ID: 3149640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative studies on human activators of plasminogen.
    Mackie M; Booth NA; Bennett B
    Br J Haematol; 1981 Jan; 47(1):77-90. PubMed ID: 6449216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of plasminogen activation protects against ganglion cell loss in a mouse model of retinal damage.
    Zhang X; Chaudhry A; Chintala SK
    Mol Vis; 2003 Jun; 9():238-48. PubMed ID: 12813409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activities of antiplasmin and antiplasminogen activator in serous middle ear effusions.
    Hamaguchi Y; Ohi M; Sakakura Y; Miyoshi Y
    Ann Otol Rhinol Laryngol; 1985; 94(3):293-6. PubMed ID: 3925865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human articular cartilage contains an inhibitor of plasminogen activator.
    Yamada H; Stephens RW; Nakagawa T; McNicol D
    J Rheumatol; 1988 Jul; 15(7):1138-43. PubMed ID: 3139880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cyclopeptidic suicide substrate preferentially inactivates urokinase-type plasminogen activator.
    Reboud-Ravaux M; Vilain AC; Boggetto N; Maillard J; Favreau C; Xie J; Mazaleyrat JP; Wakselman M
    Biochem Biophys Res Commun; 1991 Jul; 178(1):352-9. PubMed ID: 1829886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Secretion of plasminogen activator inhibitor by cultured human epidermal cells.
    Hashimoto K; Nishioka K; Katayama I; Yoshikawa K
    Br J Dermatol; 1986 Aug; 115(2):133-8. PubMed ID: 3091060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Purification of epidermal plasminogen activator inhibitor.
    Hibino T; Izaki S; Izaki M
    FEBS Lett; 1986 Nov; 208(2):273-7. PubMed ID: 3096778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The influence of the polyphenols of cider on plasmin and plasminogen activators.
    Ogston D; Lea AG; Langhorne P; Wilson SB
    Br J Haematol; 1985 Aug; 60(4):705-13. PubMed ID: 3161536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrinolysis in health and disease: severe abnormalities in systemic lupus erythematosus.
    Glas-Greenwalt P; Kant KS; Allen C; Pollak VE
    J Lab Clin Med; 1984 Dec; 104(6):962-76. PubMed ID: 6239000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor from human fibrosarcoma cells binds urokinase-type plasminogen activator, but not its proenzyme.
    Andreasen PA; Nielsen LS; Kristensen P; Grøndahl-Hansen J; Skriver L; Danø K
    J Biol Chem; 1986 Jun; 261(17):7644-51. PubMed ID: 3086313
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proenzyme to urokinase-type plasminogen activator in human colon cancer: in vitro inhibition by monocyte minactivin after proteolytic activation.
    Stephens RW; Fordham CJ; Doe WF
    Eur J Cancer Clin Oncol; 1987 Feb; 23(2):213-22. PubMed ID: 2965017
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification of a plasminogen activator inhibitor indistinguishable from alpha1-antitrypsin and an urokinase inhibitor in pregnancy plasma.
    Clemmensen I; Thorsen S; Müllertz S
    Haemostasis; 1976; 5(4):218-30. PubMed ID: 826461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The behavior of alpha2-plasmin inhibitor in fibrinolytic states.
    Aoki N; Moroi M; Matsuda M; Tachiya K
    J Clin Invest; 1977 Aug; 60(2):361-9. PubMed ID: 68962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the target specificity of plasminogen activator inhibitor 1: the role of heparin, vitronectin, and the reactive site.
    Keijer J; Linders M; Wegman JJ; Ehrlich HJ; Mertens K; Pannekoek H
    Blood; 1991 Sep; 78(5):1254-61. PubMed ID: 1715220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasminogen activators in alcoholic cirrhosis: demonstration of increased tissue type and urokinase type activator.
    Booth NA; Anderson JA; Bennett B
    J Clin Pathol; 1984 Jul; 37(7):772-7. PubMed ID: 6235248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amiloride selectively inhibits the urokinase-type plasminogen activator.
    Vassalli JD; Belin D
    FEBS Lett; 1987 Apr; 214(1):187-91. PubMed ID: 3106085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.